Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12(8):535–49. https://doi.org/10.1038/nrmicro3295. (Epub 2014/07/01. PubMed PMID: 24975322).
Article CAS PubMed Google Scholar
Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69(2):200–35. https://doi.org/10.1124/pr.116.012658. (Epub 2017/03/31. PubMed PMID: 28356439; PubMed Central PMCID: PMCPMC5394922).
Article CAS PubMed PubMed Central Google Scholar
Zhang S, Masuyer G, Zhang J, Shen Y, Lundin D, Henriksson L, et al. Identification and characterization of a novel botulinum neurotoxin. Nat Commun. 2017;8:14130. https://doi.org/10.1038/ncomms14130. (Epub 2017/08/05. PubMed PMID: 28770820; PubMed Central PMCID: PMCPMC5543303 62/360,239) for medical use of BoNT/X, with P.S., S.Z. and M.D. as inventors).
Article CAS PubMed PubMed Central Google Scholar
Alimohammadi M, Punga AR. Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations. Toxins (Basel). 2017;9(11). Epub 2017/10/31. https://doi.org/10.3390/toxins9110352. PubMed PMID: 29084148; PubMed Central PMCID: PMCPMC5705967.
Kim DW, Lee SK, Ahnn J. Botulinum toxin as a pain killer: players and actions in antinociception. Toxins (Basel). 2015;7(7):2435–53. https://doi.org/10.3390/toxins7072435. (Epub 2015/07/03. PubMed PMID: 26134255; PubMed Central PMCID: PMCPMC4516922).
Article CAS PubMed PubMed Central Google Scholar
Matak I, Bolcskei K, Bach-Rojecky L, Helyes Z. Mechanisms of botulinum toxin type A action on pain. Toxins (Basel). 2019. https://doi.org/10.3390/toxins11080459. (Epub 2019/08/08. PubMed PMID: 31387301; PubMed Central PMCID: PMCPMC6723487).
Article PubMed PubMed Central Google Scholar
Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107(1–2):125–33. https://doi.org/10.1016/j.pain.2003.10.008. (Epub 2004/01/13 PubMed PMID: 14715398).
Article CAS PubMed Google Scholar
Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. 2002;18(6 Suppl):S125–32. https://doi.org/10.1097/00002508-200211001-00003. (Epub 2003/02/07 PubMed PMID: 12569959).
Bach-Rojecky L, Lackovic Z. Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Behav. 2009;94(2):234–8. https://doi.org/10.1016/j.pbb.2009.08.012. (Epub 2009/09/08 PubMed PMID: 19732788).
Article CAS PubMed Google Scholar
Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience. 2011;186:201–7. https://doi.org/10.1016/j.neuroscience.2011.04.026. (Epub 2011/05/05 PubMed PMID: 21539899).
Article CAS PubMed Google Scholar
Drinovac V, Bach-Rojecky L, Lackovic Z. Association of antinociceptive action of botulinum toxin type A with GABA-A receptor. J Neural Transm (Vienna). 2014;121(6):665–9. https://doi.org/10.1007/s00702-013-1150-6. (Epub 2014/01/15 PubMed PMID: 24420081).
Article CAS PubMed Google Scholar
Manuel Munoz-Lora VR, Abdalla HB, Del Bel Cury AA, Clemente-Napimoga JT. Modulatory effect of botulinum toxin type A on the microglial P2X7/CatS/FKN activated-pathway in antigen-induced arthritis of the temporomandibular joint of rats. Toxicon. 2020;187:116–21. https://doi.org/10.1016/j.toxicon.2020.08.027. (Epub 2020/09/04 PubMed PMID: 32882256).
Article CAS PubMed Google Scholar
Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001;56(10):1290–3. https://doi.org/10.1212/wnl.56.10.1290. (Epub 2001/05/29 PubMed PMID: 11376175).
Article CAS PubMed Google Scholar
Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14. https://doi.org/10.1177/0333102410364677. (Epub 2010/07/22 PubMed PMID: 20647171).
Article CAS PubMed Google Scholar
Attal N, de Andrade DC, Adam F, Ranoux D, Teixeira MJ, Galhardoni R, et al. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016;15(6):555–65. https://doi.org/10.1016/S1474-4422(16)00017-X. (Epub 2016/03/08 PubMed PMID: 26947719).
Article CAS PubMed Google Scholar
Chen CL, Meng E. Can botulinum toxin A play a role in treatment of chronic pelvic pain syndrome in female patients?-Clinical and animal evidence. Toxins (Basel). 2020. https://doi.org/10.3390/toxins12020110. (Epub 2020/02/14. PubMed PMID: 32050685; PubMed Central PMCID: PMCPMC7076794).
Article PubMed PubMed Central Google Scholar
Barjandi G, Svedenlof J, Jasim H, Collin M, Hedenberg-Magnusson B, Christidis N, et al. Clinical aspects of mastication myalgia-an overview. Front Pain Res (Lausanne). 2023;4:1306475. https://doi.org/10.3389/fpain.2023.1306475. (PubMed PMID: 38264542; PubMed Central PMCID: PMCPMC10803665).
Al-Moraissi EA, Alradom J, Aladashi O, Goddard G, Christidis N. Needling therapies in the management of myofascial pain of the masticatory muscles: a network meta-analysis of randomised clinical trials. J Oral Rehabil. 2020;47(7):910–22. https://doi.org/10.1111/joor.12960. (Epub 2020/03/12 PubMed PMID: 32159870).
Al-Moraissi EA, Conti PCR, Alyahya A, Alkebsi K, Elsharkawy A, Christidis N. The hierarchy of different treatments for myogenous temporomandibular disorders: a systematic review and network meta-analysis of randomized clinical trials. Oral Maxillofac Surg. 2021;21:21. https://doi.org/10.1007/s10006-021-01009-y. (PubMed PMID: 34674093).
Alkhutari AS, Alyahya A, Conti PCR, Christidis N, Al-Moraissi EA. Is the therapeutic effect of occlusal stabilization appliances more than just placebo effect in the management of painful temporomandibular disorders? A network meta-analysis of randomized clinical trials. J Prosthet Dent. 2021;126(1):24–32. https://doi.org/10.1016/j.prosdent.2020.08.015. (PubMedPMID:WOS:000670295900006).
Christidis N, Al-Moraissi EA, Barjandi G, Svedenlof J, Jasim H, Christidis M, et al. Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis. Drugs. 2024;84(1):59–81. https://doi.org/10.1007/s40265-023-01971-9. (Epub 2023/12/16 PubMed PMID: 38103150; PubMed Central PMCID: PMCPMC10789663 Svedenlof, Hajer Jasim, Maria Christidis, and Malin Collin declare that they have no conflicts of interest that might be relevant to the contents of this manuscript).
Ohrbach R, Dworkin SF. Five-year outcomes in TMD: relationship of changes in pain to changes in physical and psychological variables. Pain. 1998;74(2–3):315–26. https://doi.org/10.1016/s0304-3959(97)00194-2. (Epub 1998/03/31 PubMed PMID: 9520246).
Article CAS PubMed Google Scholar
von Lindern JJ. Type A botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction. Acta Neurol Belg. 2001;101(1):39–41 (Epub 2001/05/31 PubMed PMID: 11379274).
Nixdorf DR, Heo G, Major PW. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain. 2002;99(3):465–73. https://doi.org/10.1016/S0304-3959(02)00240-3. (Epub 2002/10/31 PubMed PMID: 12406522).
Article CAS PubMed Google Scholar
Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg. 2008;66(8):1644–51. https://doi.org/10.1016/j.joms.2008.03.008. (Epub 2008/07/19 PubMed PMID: 18634953).
Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. Pain. 2011;152(9):1988–96. https://doi.org/10.1016/j.pain.2011.03.036. (Epub 2011/04/26 PubMed PMID: 21514731).
Article CAS PubMed Google Scholar
Patel AA, Lerner MZ, Blitzer A. IncobotulinumtoxinA injection for temporomandibular joint disorder. Ann Otol Rhinol Laryngol. 2017;126(4):328–33. https://doi.org/10.1177/0003489417693013. (Epub 2017/03/16. PubMed PMID: 28290229).
De la Torre Canales G, Alvarez-Pinzon N, Muñoz-Lora VRM, Vieira Peroni L, Farias Gomes A, Sánchez-Ayala A, et al. Efficacy and safety of botulinum toxin type a on persistent myofascial pain: a randomized clinical trial. Toxins (Basel). 2020. https://doi.org/10.3390/toxins12060395. (Epub 2020/06/19. PubMed PMID: 32549196; PubMed Central PMCID: PMCPMC7354430).
留言 (0)